Leukemia Research
Volume 28, Issue 3 , Pages 275-284 , March 2004

A new human natural killer leukemia cell line, IMC-1. A complex chromosomal rearrangement defined by spectral karyotyping: functional and cytogenetic characterization

  • I-Ming Chen

      Affiliations

    • Department of Pathology, University of New Mexico School of Medicine, 900 Camino de Salud NE, Albuquerque, NM 87131-5636, USA
    • ,
  • Margaret Whalen

      Affiliations

    • Department of Medicine, Cancer Center, Center for Molecular and Cellular Diagnostics, 900 Camino de Salud NE, Albuquerque, NM 87131-5636, USA
    • ,
  • Arthur Bankhurst

      Affiliations

    • Department of Medicine, Cancer Center, Center for Molecular and Cellular Diagnostics, 900 Camino de Salud NE, Albuquerque, NM 87131-5636, USA
    • Corresponding Author InformationCorresponding author. Present address: Department of Internal Medicine, MSC10 5550, 1 University of New Mexico, Albuquerque, NM 87131-0001, USA. Tel.: +1-505-272-4761; fax: +1-505-272-3624.
    • ,
  • Cordelia E Sever

      Affiliations

    • Department of Pathology, University of New Mexico School of Medicine, 900 Camino de Salud NE, Albuquerque, NM 87131-5636, USA
    • ,
  • Rashmi Doshi

      Affiliations

    • Department of Medicine, Cancer Center, Center for Molecular and Cellular Diagnostics, 900 Camino de Salud NE, Albuquerque, NM 87131-5636, USA
    • ,
  • David Hardekopf

      Affiliations

    • Department of Pathology, University of New Mexico School of Medicine, 900 Camino de Salud NE, Albuquerque, NM 87131-5636, USA
    • ,
  • Karen Montgomery

      Affiliations

    • Department of Pathology, University of New Mexico School of Medicine, 900 Camino de Salud NE, Albuquerque, NM 87131-5636, USA
    • ,
  • Cheryl L Willman

      Affiliations

    • Department of Pathology, University of New Mexico School of Medicine, 900 Camino de Salud NE, Albuquerque, NM 87131-5636, USA

Received 18 March 2003 ,Accepted 25 June 2003.

References 

  1. Lanier LL, Phillips JH, Hackett J, Tutt M, Kumar V. Natural killer cells: definition of a cell type rather than a function. J. Immunol. 1986;137:2735–2739
  2. Reynolds CW, Ortaldo JR. Natural killer cell activity: the definition of a function rather than a cell type. Immunol. Today. 1987;8:172–174
  3. Hercend T, Schmidt RE. Characteristics and uses of natural killer cells. Immunol. Today. 1988;9:291–293
  4. Trinchieri G. Biology of natural killer cells. Adv. Immunol. 1989;47:187–236
  5. Drexler H, Matsuo Y. Malignant hematopoietic cell lines: in vitro models for the study of natural killer cell leukemia–lymphoma. Leukemia. 2000;14:777–782
  6. Yagita M, Huang C, Umehara H, Matsuo Y, Tabata R, Miyake M, et al.  A novel natural killer cell line (KHYG-1) from a patient with aggressive natural killer cell leukemia carrying a p53 point mutation. Leukemia. 2000;14:922–930
  7. Di Noto R, Pane F, Camera A, Luciano L, Barone M, Lo Pardo C, et al.  Characterization of two novel cell lines, DERL-2 (CD56+/CD3+/TCT_+) and DERL-7 (CD56+/CD3−/TCR_−), derived from a single patient with CD56+ non-Hodgkin’s lymphoma. Leukemia. 2001;15:1641–1649
  8. Yodoi J, Teshigawara K, Nikaido T, Fukui K, Noma T, Honjo T, et al.  TCGF(IL-2)receptor inducing factor(s). I. Regulation of IL-2 receptor on a natural killer-like cell line (YT-cells). J. Immunol. 1985;134(3):1623–1630
  9. MacLeod RAF, Nagel S, Kaufmann M, Greulich-Bode K, Drexler HG. Multicolor-FISH analysis of a natural killer cell line (NK-92). Leuk. Res. 2002;26:1027–1033
  10. Cosentino LM, Cathcart MK. A multi-step isolation scheme for obtaining CD16+ human natural killer cells. J. Immunol. Methods. 1987;103:195–204
  11. Boyum A. Isolation of leucocytes from human blood. A two-phase system for removal of red cells with methylcellulose as erythrocyte-aggregating agent. Scand. J. Clin. Lab. Invest. 1968;21(Suppl. 97):9–29
  12. Ling NR, Bishop S, Jefferis R. Use of antibody-coated red cells for the sensitive detection of antigen and in rosette tests for cells bearing surface immunoglobulins. J. Immunol. Methods. 1977;15:279–289
  13. Perussia B, Starr S, Abraham S, Fanning V, Trinchieri G. Human natural killer cells analyzed by B73.1, a monoclonal antibody blocking Fc receptor functions. 1. Characterization of the lymphocyte subset reactive with B73.1. J. Immunol. 1983;130(5):2133–2141
  14. Foucar K, Chen I-M, Crago S. Organization and operation of a flow cytometric immunophenotyping laboratory. Semin. Diagn. Pathol. 1989;6:13–36
  15. Whalen MM, Doshi RN, Bankhurst AD. Effects of pertussis toxin treatment on human natural killer cell function. Immunology. 1992;76:402–407
  16. Mitelman F, editor. ISCN. An international system for human cytogenetic nomenclature. Basel: Karger; 1995.
  17. Semenzato G, Pandolfi F, Chisesi T, De Rossi G, Pizzolo G, Zambello R, et al.  The lymphoproliferative disease of granular lymphocytes. A heterogeneous disorder ranging from indolent to aggressive conditions. Cancer. 1987;60:2971–2978
  18. McKenna RW. Lymphoproliferative disorder of granular lymphocytes. More questions than answers. Arch. Pathol. Lab. Med. 1992;116:235–237
  19. Schmidt RE, Bartley G, Levine H, Schlossman SF, Ritz J. Functional characterization of LFA-1 antigens in the interaction of human NK clones and target cells. J. Immunol. 1985;135:1020–1025
  20. Timonen T, Patarroyo M, Gahmberg GC. CD11a–c/CD18 and GP84 (LB-2) adhesion molecules on human large granular lymphocytes and their participation in natural killing. J. Immunol. 1988;141:1041–1046
  21. Robertson MJ, Caligiuri MA, Manley TJ, Levine H, Ritz J. Human natural killer cell adhesion molecules: differential expression after activation and participation in cytolysis. J. Immunol. 1990;145:3194–3201
  22. Nitta T, Yagita H, Sato K, Okumura K. Involvement of CD56 (NKH1/Leu-19 antigen) as an adhesion molecule in natural killer–target cell interaction. J. Exp. Med. 1989;170:1757–1761
  23. Suzuki N, Suzuki T, Engleman EG. Evidence for the involvement of CD56 molecules in alloantigen-specific recognition by human natural killer cells. J. Exp. Med. 1991;173:1451–1461
  24. van de Griend RJ, Bolhuis RLH. In vitro expansion and analysis of cloned cytotoxic T cells derived from patients with chronic T γ lymphoproliferative disorders. Blood. 1985;64:1002–1009
  25. Pistoia V, Carroll AJ, Prasthofer EF, Tilden AB, Zuckerman KS, Ferrarini M, et al.  Establishment of Tac-negative, interleukin-2-dependent cytotoxic cell lines from large granular lymphocytes (LGL) of patients with expanded LGL populations. J. Clin. Immunol. 1986;6(6):457–466
  26. Scott-Algara D, Vuillier F, Gauguet C, Dighiero G. Establishment of long term cell lines from 2 patients with large granular lymphocyte lymphocytosis displaying an unusual phenotype. Nouv. Rev. Fr. Hematol. 1991;33:237–243
  27. Lanier LL, Le AM, Civin CI, Loken MR, Phillips JH. The relationship of CD16 (Leu-11) and Leu-19 (NKH1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. J. Immunol. 1986;136:4480–4486
  28. Nagler A, Lanier LL, Cwirla S, Phillips JH. Comparative studies of human FcRIII-positive and negative natural killer cells. J. Immunol. 1989;143:3183–3191
  29. Miller JS, Verfaillie C, McGlave P. The generation of human natural killer cells from CD34+/DR− primitive progenitors in long-term bone marrow culture. Blood. 1992;80:2182–2187
  30. Sheridan W, Winton EF, Chan WC, Gordon DS, Vogler WR, Phillips C, et al.  Leukemia of non-T lineage natural killer cells. Blood. 1988;72:1701–1707
  31. Ellis TM, Creekmore SP, McMannis JD, Braun DP, Harris JA, Fisher RI. Appearance and phenotypic characterization of circulating Leu-19 cells in cancer patients receiving recombinant interleukin-2. Cancer Res. 1988;48:6597–6602
  32. Weil-Hillman G, Fisch P, Prieve AF, Sosman JA, Hank JA, Sondel PM. Lymphokine-activated killer activity induced by in vivo interleukin-2 therapy: predominant role for lymphocytes with increased expression of CD2and Leu-19 but negative expression of CD16 antigens. Cancer Res. 1989;49:3680–3688
  33. Robertson MJ, Ritz J. Biology and clinical relevance of human natural killer cells. Blood. 1990;76:2421–2438
  34. Pizzolo G, Rigo A, Zanotti R, Vinante F, Vincenzi C, Cassatella M, et al.  α (p55) and β (p75) chains of the interleukin-2 receptor are expressed by AML blasts. Leukemia. 1993;7:418–425
  35. Wong N, Wong KF, Chan JK, Johnson PJ. Chromosomal translocations are common in natural killer-cell lymphoma/leukemia as shown by spectral karyotyping. Hum. Pathol. 2000;31:771–774
  36. Wong KF, Zhang YM, Chan JK. Cytogenetic abnormalities in natural killer cell lymphoma/leukemia—is there a consistent pattern?. Leuk. Lymph. 1999;34:241–250
  37. Siu LL, Chan V, Chan JK, Wong KF, Liang R, Kwong YL. Consistent patterns of allelic loss in natural killer cell lymphoma. Am. J. Pathol. 2000;157:1803–1809
  38. Fernandez L, Pope B, Lee C, Zayed E. Aggressive natural killer cell leukemia in an adult with establishment of an NK cell line. Blood. 1986;67:925–930
  39. Suto Y, Maenaka K, Yabe T, Hirai M, Tokunaga K, Tadok K, et al.  Chromosomal localization of the human natural killer cell class I receptor family genes to 19q13.4 by fluorescence in situ hybridization. Genomics. 1996;35:270–276
  40. www.ncbi.nlm.nih.gov/mapview/.
  41. Zhou XZ, Lu KP. The Pin2/TRF1-interacting protein PinX1 is a potent telomerase inhibitor. Cell. 2001;107:347–359
  42. Yokoyama WM, Plougastel BF. Immune functions encoded by the natural killer gene complex. Nat. Rev. Immunol. 2003;3:304–316
  43. Mitelman F, Johansson B, Mertens F, editors. Mitelman database of chromosome aberrations in cancer; 2002 (http://cgap.nci.nih.gov/Chromosomes/Mitelman).
  44. Berger C, Day P, Meier G, Zirgg W, Bossart W, Nadal D. Dynamics of Epstein–Barr virus DNA levels in serum during EVB associated disease. J. Med. Virol. 2001;64:505–512

PII: S0145-2126(03)00254-6

doi: 10.1016/S0145-2126(03)00254-6

Leukemia Research
Volume 28, Issue 3 , Pages 275-284 , March 2004

Article Tools

* Image Usage & Resolution